Eton Pharmaceuticals (NASDAQ:ETON) Posts Quarterly Earnings Results, Beats Expectations By $0.19 EPS

Eton Pharmaceuticals (NASDAQ:ETON) announced its quarterly earnings results on Thursday. The company reported $0.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.19, FiscalAI reports. The company had revenue of $57.93 million for the quarter, compared to analyst estimates of $41.98 million. Eton Pharmaceuticals had a net margin of 35.35% and a return on equity of 144.74%.

Here are the key takeaways from Eton Pharmaceuticals’ conference call:

• Eton reported record third-quarter revenue of $57.9 million, up 158% year over year, with growth from HEMANGEOL and strength across its portfolio. The company raised 2026 revenue guidance to more than $175 million.
• Profitability and cash generation improved sharply: adjusted gross margin was 80%, adjusted EBITDA was $28.5 million (49% of revenue), and cash from operations was $35 million. Eton ended the quarter with $55.6 million in cash after a $5 million debt prepayment, and now expects a full-year adjusted EBITDA margin above 40%.
• LIBERVANT adds a potential near-term growth driver in seizure-cluster treatment; Eton expects to launch in April 2027, subject to FDA approval and resolution of exclusivity restrictions. Management sees opportunity for its portable buccal film in a U.S. market it estimates exceeds $450 million annually.
• Management sees significant pipeline upside, particularly from ASN-001, a topical hemangioma treatment it believes could serve a broader population than HEMANGEOL; a short bioavailability study is underway, with an NDA submission targeted for mid-2027 and a potential 2028 launch. Other programs include a planned 2027 study of ET-900 for infantile spasms and a potential 2027 launch for glibenclamide oral suspension.
• ET-700’s proof-of-concept study found treatment-related adverse events in 1 of 12 participants versus 8 of 12 on GALZIN, but it blocked copper absorption less effectively than GALZIN. Eton attributed the efficacy gap to a release profile it says was too slow and plans to test faster-release formulations in 2027, leaving the program’s next steps dependent on further results.

Eton Pharmaceuticals Trading Up 19.7%

Shares of NASDAQ:ETON traded up $9.31 during mid-day trading on Friday, reaching $56.46. 1,269,987 shares of the company’s stock were exchanged, compared to its average volume of 415,837. The firm has a market capitalization of $1.61 billion, a price-to-earnings ratio of 37.39 and a beta of 0.89. The business’s fifty day moving average price is $54.80 and its 200-day moving average price is $36.46. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.30 and a current ratio of 1.52. Eton Pharmaceuticals has a twelve month low of $14.27 and a twelve month high of $66.37.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on ETON shares. Zacks Research upgraded shares of Eton Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 12th. Craig Hallum reaffirmed a “buy” rating and set a $78.00 target price on shares of Eton Pharmaceuticals in a research note on Thursday, October 15th. B. Riley Financial reiterated a “buy” rating and set a $70.00 price target (up from $40.00) on shares of Eton Pharmaceuticals in a report on Friday, August 14th. Weiss Ratings upgraded shares of Eton Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Tuesday, September 22nd. Finally, Canaccord Genuity Group increased their price target on Eton Pharmaceuticals from $68.00 to $80.00 and gave the company a “buy” rating in a research note on Friday. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat.com, Eton Pharmaceuticals presently has an average rating of “Buy” and an average target price of $77.00.

Insider Buying and Selling at Eton Pharmaceuticals

In related news, insider David Krempa sold 4,166 shares of the firm’s stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $55.07, for a total transaction of $229,421.62. Following the completion of the transaction, the insider directly owned 43,381 shares of the company’s stock, valued at $2,388,991.67. This trade represents a 8.76% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Paul V. Maier sold 50,000 shares of Eton Pharmaceuticals stock in a transaction dated Friday, August 28th. The stock was sold at an average price of $59.07, for a total value of $2,953,500.00. Following the transaction, the director directly owned 59,745 shares in the company, valued at $3,529,137.15. The trade was a 45.56% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 79,166 shares of company stock worth $4,809,672. 16.49% of the stock is currently owned by insiders.

Trending Headlines about Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Q3 product sales reached a record $57.9 million, up 158% year over year. Eton reported diluted GAAP EPS of $1.06 and non-GAAP EPS of $0.50, and said it exceeded a $200 million annualized revenue run rate five quarters ahead of schedule. Eton Q3 results
• Positive Sentiment: Management raised its 2026 revenue outlook to more than $175 million, from more than $145 million, and lifted its adjusted EBITDA margin outlook to above 40%, from above 35%. The stronger forecast reinforces expectations for continued growth and improving profitability. Eton earnings and guidance
• Positive Sentiment: Canaccord Genuity and HC Wainwright both raised their price targets to $80 and maintained Buy ratings, signaling confidence in Eton’s prospects. Canaccord Genuity rating HC Wainwright rating
• Neutral Sentiment: Eton announced preliminary results from an ET-700 pilot study assessing copper absorption inhibition and gastrointestinal tolerability. The brief report does not provide enough detail to judge the findings’ significance for the pipeline. ET-700 pilot study update

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing treatments for rare diseases and other conditions with limited therapeutic options. The company generally pursues products that address unmet medical needs, including medicines for pediatric and orphan indications.

Eton’s commercial portfolio has included Alkindi Sprinkle, an oral hydrocortisone formulation used as replacement therapy in young children with adrenal insufficiency, and Eprontia, an oral solution formulation of topiramate.